When should zaleplon be used instead of low‑dose doxepin or trazodone for insomnia, and what are the appropriate dosing and safety considerations?

Zaleplon vs Doxepin vs Trazodone for Insomnia

For sleep-onset insomnia, use zaleplon 10 mg; for sleep-maintenance insomnia, use low-dose doxepin (3-6 mg); avoid trazodone entirely as it lacks evidence and carries significant risks.

Clinical Decision Algorithm

Step 1: Identify the Insomnia Pattern

Sleep-Onset Insomnia (difficulty falling asleep):

• First choice: Zaleplon 10 mg at bedtime 1
• Reduces sleep latency by 10-20 minutes (15-30% improvement) 2
• Can be taken middle-of-night if ≥4 hours remain before awakening 2
• Elderly patients: Start with 5 mg 2

Sleep-Maintenance Insomnia (difficulty staying asleep):

• First choice: Low-dose doxepin 3-6 mg 1, 3
• Specifically indicated for sleep maintenance, not sleep onset
• Improved sleep quality and total sleep time in elderly adults 3
• No black box warning for suicide at hypnotic doses, though risk cannot be excluded 3

Both Sleep-Onset and Maintenance:

• Consider eszopiclone or zolpidem extended-release instead 1
• Zaleplon is NOT appropriate for maintenance issues 2

Step 2: Why NOT Trazodone

The American Academy of Sleep Medicine explicitly recommends AGAINST trazodone 1. The evidence is clear:

• No difference in sleep efficiency vs placebo 3
• No improvement in sleep onset latency, total sleep time, or wake after sleep onset 3
• Only subjective sleep quality showed minimal benefit 3
• Studies were very short duration (mean 1.7 weeks) with poor quality evidence 3
• Significant adverse effects outweigh minimal benefits 3
• Despite being commonly prescribed off-label, it lacks supporting evidence 4

The 2020 VA/DoD guidelines reinforced this, stating the low-quality evidence for trazodone was outweighed by its adverse effect profile 3.

Dosing Specifications

Zaleplon

• Non-elderly adults: 10 mg at bedtime (can use 20 mg if 10 mg ineffective, though higher adverse event risk) 1, 2
• Elderly or debilitated: 5 mg at bedtime 2
• Hepatic impairment: 5 mg maximum 2
• Critical timing: Take immediately before bed OR middle-of-night if ≥4 hours of sleep time remain 2
• Food interaction: High-fat meals delay absorption by 2 hours and reduce effectiveness by 35%—take on empty stomach 2

Low-Dose Doxepin

• Adults and elderly: 3-6 mg at bedtime 1, 3
• Do NOT confuse with antidepressant doses (75-300 mg)
• Specifically formulated for insomnia at these low doses
• No dose adjustment needed for renal impairment 3

Safety Considerations

Zaleplon Safety Profile

• Minimal next-day impairment at 5-10 mg doses 2, 5, 6
• Memory impairment present only at 1 hour post-dose, resolved by 2-4 hours 2
• No rebound insomnia after discontinuation, even after 12 months of use 2, 5
• No tolerance development during 5 weeks to 12 months of treatment 5
• Low abuse potential compared to benzodiazepines 6
• Headache most common side effect (similar rate to placebo) 5

Doxepin Safety Profile

• No significant difference in adverse events vs placebo in RCTs 3
• Adverse events may increase with longer treatment duration 3
• Suicide risk at hypnotic doses is unknown but cannot be excluded 3
• Generally well-tolerated in elderly 3
• Lower risk of somnolence and headache compared to most other agents 7

Common Pitfalls to Avoid

1. Don't use zaleplon for sleep maintenance—its ultra-short half-life (1 hour) makes it ineffective for staying asleep 2

2. Don't prescribe trazodone despite its popularity—it's one of the most commonly prescribed insomnia medications but lacks evidence and has negative guideline recommendations 4

3. Don't use antidepressant doses of doxepin for insomnia—hypnotic dosing is 3-6 mg, not 75-300 mg 1, 3

4. Don't give zaleplon with food—high-fat meals significantly impair absorption and effectiveness 2

5. Don't use benzodiazepines routinely—risks of dependency, falls, cognitive impairment, and respiratory depression outweigh benefits 3

Strength of Evidence

All recommendations are based on WEAK evidence under GRADE criteria 1, reflecting:

• Industry funding of most trials (publication bias risk)
• Small number of trials per agent
• Data heterogeneity

However, "weak" refers to certainty of evidence, not ineffectiveness. The distinction is critical: zaleplon and doxepin have positive recommendations (use them), while trazodone has a negative recommendation (don't use it) 1.

Special Populations

Elderly patients:

• Zaleplon 5 mg preferred starting dose 2
• Doxepin 3-6 mg equally effective as in younger adults 3
• Both agents studied specifically in elderly populations with favorable results 2

Hepatic impairment:

• Zaleplon: Maximum 5 mg; avoid in severe impairment 2
• Doxepin: Use caution; no specific dose adjustment data

Renal impairment:

• Zaleplon: No adjustment needed for mild-moderate impairment 2
• Doxepin: No adjustment needed 3